Amgen Inc (AMGN)vsEquinix Inc (EQIX)
AMGN
Amgen Inc
$349.58
+0.32%
HEALTHCARE · Cap: $177.16B
EQIX
Equinix Inc
$1,089.15
+1.21%
REAL ESTATE · Cap: $105.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Amgen Inc generates 291% more annual revenue ($37.22B vs $9.53B). AMGN leads profitability with a 21.0% profit margin vs 14.9%. AMGN appears more attractively valued with a PEG of 2.18. AMGN earns a higher WallStSmart Score of 62/100 (C+).
AMGN
Buy62
out of 100
Grade: C+
EQIX
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-25.9%
Fair Value
$277.75
Current Price
$349.58
$71.83 premium
Intrinsic value data unavailable for EQIX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 85 in profit
Strong operational efficiency at 33.8%
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Generating 1.5B in free cash flow
Large-cap with strong market position
Strong operational efficiency at 24.3%
Earnings expanding 20.0% YoY
Areas to Watch
Expensive relative to growth rate
4.4% earnings growth
Trading at 20.5x book value
Distress zone — elevated risk
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.
Bull Case : EQIX
The strongest argument for EQIX centers on Market Cap, Operating Margin, EPS Growth. Revenue growth of 12.1% demonstrates continued momentum.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, EPS Growth, Price/Book. Debt-to-equity of 6.24 is elevated, increasing financial risk.
Bear Case : EQIX
The primary concerns for EQIX are Debt/Equity, Piotroski F-Score, PEG Ratio. A P/E of 74.1x leaves little room for execution misses. Debt-to-equity of 1.63 is elevated, increasing financial risk.
Key Dynamics to Monitor
AMGN profiles as a mature stock while EQIX is a value play — different risk/reward profiles.
EQIX carries more volatility with a beta of 1.00 — expect wider price swings.
EQIX is growing revenue faster at 12.1% — sustainability is the question.
AMGN generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
AMGN scores higher overall (62/100 vs 54/100), backed by strong 21.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Equinix Inc
REAL ESTATE · REIT - SPECIALTY · USA
Equinix, Inc. is an American multinational company headquartered in Redwood City, California, that specializes in Internet connection and data centers.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?